iPSC-derived mesenchymal stromal cell therapy (Cynata Therapeutics)

N/A

Report date: 2025/06/11 10:52:46

Base Information

Drug NameiPSC-derived mesenchymal stromal cell therapy (Cynata Therapeutics)
Drug Alias NameiPSC-derived MSC therapy (Cynata Therapeutics)mesenchymoangioblast-derived mesenchymal stem cell therapy (Cynata Therapeutics)
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsRejection of renal transplantation
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCynata Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesCynata Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsRejection of renal transplantation
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A